BioMarin CEO Jean-Jacques Bienaimé retiring; Alexander Hardy appointed new CEO

BIOMARIN PHARMACEUTICAL INC

Jean-Jacques Bienaimé retires as President, CEO and Chairman on Nov 30, 2023; remains on board until 2024 annual meeting.
Alexander Hardy (ex-Genentech CEO) becomes President and CEO and joins board effective Dec 1, 2023.
Hardy receives $1,050,000 annual base salary, $900,000 signing bonus, and ~$15.5M in equity grants with multi-year vesting.
Bienaimé eligible for 2023 bonus at 120% of base salary if he remains director/consultant; consulting pays $146k/mo then $73k/mo.
Lead independent director Richard A. Meier becomes Board Chair effective Dec 1, 2023.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Richard A. Meier

Chair of the Board

BMRN · BIOMARIN PHARMACEUTICAL INC

Effective: 2023-12-01
Filed: November 3, 2023, 7:59 PM ET

Richard A. Meier, BioMarin’s lead independent director, will assume the role of Chair of the Board, effective December 1, 2023.

Departed

Jean-Jacques Bienaimé

President, Chairman and Chief Executive Officer

BMRN · BIOMARIN PHARMACEUTICAL INC

Effective: 2023-11-30
Successor: Alexander Hardy
Filed: November 3, 2023, 7:59 PM ET

Jean-Jacques Bienaimé will retire as the Company’s President, Chairman and Chief Executive Officer effective as of close of business on November 30, 2023

Appointed

Alexander Hardy

President and Chief Executive Officer

BMRN · BIOMARIN PHARMACEUTICAL INC

Effective: 2023-12-01
Filed: November 3, 2023, 7:59 PM ET

the Company announced the appointment of Alexander Hardy, age 55, to serve as the Company’s President and Chief Executive Officer and as a member of the Board, effective as of December 1, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Richard A. Meier was appointed as Chair of the Board at BIOMARIN PHARMACEUTICAL INC.

Action: appointed
Role: Chair of the Board

Exact text from the filing

Richard A. Meier, BioMarin’s lead independent director, will assume the role of Chair of the Board, effective December 1, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Jean-Jacques Bienaimé retired as President, Chairman and Chief Executive Officer at BIOMARIN PHARMACEUTICAL INC.

Action: retired
Role: President, Chairman and Chief Executive Officer

Exact text from the filing

Jean-Jacques Bienaimé will retire as the Company’s President, Chairman and Chief Executive Officer effective as of close of business on November 30, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Alexander Hardy was appointed as President and Chief Executive Officer at BIOMARIN PHARMACEUTICAL INC.

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

the Company announced the appointment of Alexander Hardy, age 55, to serve as the Company’s President and Chief Executive Officer and as a member of the Board, effective as of December 1, 2023

View on SEC.gov

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001193125-23-270370

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.